Odonate, Inc. Overview
Industry: Shell Companies
Sector: Financial Services
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
Odonate, Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Odonate, Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Odonate, Inc. Competitors
Odonate, Inc. operates in the Shell Companies industry within the Financial Services sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans